0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Influence of Sex Hormones on Plasma Endothelin Levels

Kees H. Polderman, MD; Coen D. A. Stehouwer, MD; Gerard J. van Kamp, PhD; Gustaaf A. Dekker, MD, PhD; Freek W. A. Verheugt, MD, PhD; and Louis J. G. Gooren, MD, PhD
[+] Article and Author Information

From Free University Hospital, Amsterdam, The Netherlands. Requests for Reprints: Kees H. Polderman, MD, Department of Internal Medicine, Free University Hospital, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. Acknowledgments: The authors thank J.A.J. Megens for assistance in the logistics of this study and for recruitment of patients; and J. van Bezu for technical assistance.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1993;118(6):429-432. doi:10.7326/0003-4819-118-6-199303150-00006
Text Size: A A A

Objective: To determine whether a sex-associated difference in endothelin levels exists and to assess whether this difference is mediated by sex hormones.

Design: Initial survey in healthy persons, followed by a nonrandomized intervention.

Setting: A university teaching hospital.

Patients: Twenty-three healthy men, 29 healthy women, 20 pregnant women, and 12 male-to-female and 13 female-to-male transsexual patients.

Measurements: Plasma levels of endothelin were first assessed in healthy men, healthy women, and pregnant women; subsequently, endothelin levels were determined in male-to-female and female-to-male transsexual patients both before and during cross-gender hormone treatment. This treatment involves administration of testosterone esters to women and of ethynylestradiol and cyproterone acetate to men.

Results: Endothelin levels were higher in men than in women (5.9 ± 1.2 compared with 4.17 ± 0.67 pg/mL; P < 0.01). Endothelin levels were lower in pregnant women than in age- and sex-matched nonpregnant controls (2.19 ± 0.73 compared with 4.17 ± 0.67 pg/mL; P < 0.01). In 12 male-to-female transsexuals treated with estradiol and the progestational agent cyproterone acetate, endothelin levels decreased from 8.1 ± 3.0 to 5.1 ± 2.0 pg/mL (P < 0.01). In 13 female-to-male transsexuals treated with testosterone, endothelin levels increased from 6.2 ± 1.1 to 7.8 ± 1.2 pg/mL (P < 0.01).

Conclusion: Sex hormones may modulate plasma endothelin levels, with male hormones raising levels and female hormones lowering them. This finding may be important in explaining sex-associated differences in susceptibility to atherosclerotic cardiovascular disease.

Figures

Grahic Jump Location
Figure 1.
Plasma endothelin levels in 23 men, 29 women, and 20 pregnant women.PP

Each square denotes one participant. Levels of endothelin were higher in men than in women (  <0.01) and lower in pregnant women than in nonpregnant controls ( < 0.01).

Grahic Jump Location
Grahic Jump Location
Figure 2.
Effects of cross-gender sex hormone treatment on plasma endothelin levels in transsexual patients.Left panel.PRight panel.

The thin lines show changes in individual patients; the horizontal bars indicate averages. Endothelin levels decreased in men treated with ethynylestradiol and cyproterone acetate ( < 0.01). Endothelin levels increased in biological women treated with testosterone.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Journal Club
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)